Eagle Pharmaceuticals Statistics
Total Valuation
Eagle Pharmaceuticals has a market cap or net worth of 8.47 million. The enterprise value is 65.57 million.
Market Cap | 8.47M |
Enterprise Value | 65.57M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
Earnings Date | Mar 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Eagle Pharmaceuticals has 13.02 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 13.02M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +0.01% |
Owned by Insiders (%) | 11.10% |
Owned by Institutions (%) | 39.52% |
Float | 6.31M |
Valuation Ratios
The trailing PE ratio is 0.71.
PE Ratio | 0.71 |
Forward PE | n/a |
PS Ratio | 0.03 |
PB Ratio | 0.03 |
P/TBV Ratio | 0.09 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.03, with an EV/FCF ratio of -6.98.
EV / Earnings | 5.49 |
EV / Sales | 0.25 |
EV / EBITDA | 1.03 |
EV / EBIT | 1.57 |
EV / FCF | -6.98 |
Financial Position
The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.29.
Current Ratio | 2.16 |
Quick Ratio | 1.51 |
Debt / Equity | 0.29 |
Debt / EBITDA | 1.14 |
Debt / FCF | -7.71 |
Interest Coverage | 6.85 |
Financial Efficiency
Return on equity (ROE) is 4.88% and return on invested capital (ROIC) is 8.46%.
Return on Equity (ROE) | 4.88% |
Return on Assets (ROA) | 6.63% |
Return on Capital (ROIC) | 8.46% |
Revenue Per Employee | 1.92M |
Profits Per Employee | 89,164 |
Employee Count | 134 |
Asset Turnover | 0.65 |
Inventory Turnover | 1.55 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.96% in the last 52 weeks. The beta is 0.52, so Eagle Pharmaceuticals's price volatility has been lower than the market average.
Beta (5Y) | 0.52 |
52-Week Price Change | -85.96% |
50-Day Moving Average | 0.73 |
200-Day Moving Average | 3.61 |
Relative Strength Index (RSI) | 43.38 |
Average Volume (20 Days) | 20,209 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 2.08 |
Income Statement
In the last 12 months, Eagle Pharmaceuticals had revenue of 257.55 million and earned 11.95 million in profits. Earnings per share was 0.91.
Revenue | 257.55M |
Gross Profit | 179.88M |
Operating Income | 41.71M |
Pretax Income | 29.17M |
Net Income | 11.95M |
EBITDA | 62.33M |
EBIT | 41.71M |
Earnings Per Share (EPS) | 0.91 |
Balance Sheet
The company has 15.35 million in cash and 72.45 million in debt, giving a net cash position of -57.10 million or -4.38 per share.
Cash & Cash Equivalents | 15.35M |
Total Debt | 72.45M |
Net Cash | -57.10M |
Net Cash Per Share | -4.38 |
Equity (Book Value) | 252.04M |
Book Value Per Share | 19.25 |
Working Capital | 100.62M |
Cash Flow
In the last 12 months, operating cash flow was -9.32 million and capital expenditures -74,000, giving a free cash flow of -9.39 million.
Operating Cash Flow | -9.32M |
Capital Expenditures | -74,000 |
Free Cash Flow | -9.39M |
FCF Per Share | -0.72 |
Margins
Gross margin is 69.84%, with operating and profit margins of 16.19% and 4.64%.
Gross Margin | 69.84% |
Operating Margin | 16.19% |
Pretax Margin | 11.33% |
Profit Margin | 4.64% |
EBITDA Margin | 24.20% |
EBIT Margin | 16.19% |
FCF Margin | n/a |
Dividends & Yields
Eagle Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.21% |
Shareholder Yield | -2.21% |
Earnings Yield | 140.26% |
FCF Yield | -110.95% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Eagle Pharmaceuticals has an Altman Z-Score of 3.26.
Altman Z-Score | 3.26 |
Piotroski F-Score | n/a |